This leaflet answers some common questions about DBL Cisplatin Injection. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

The most common reason for cisplatin-ineligibility is renal function impairment. Up to 40% of patients with bladder cancer have renal impairment, defined as a creatinine clearance ≤60 ml/min ...

Detailed price information for Fennec Pharmaceuticals Inc (FENC-Q) from The Globe and Mail including charting and trades.

has launched PEDMARQSI (sodium thiosulfate injection) in Germany ... approved therapy in the EU and U.K. for the prevention of cisplatin-induced ototoxicity in pediatric cancer patients.